Drug Trial Radar · NCT04762355
Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects
Last checked: Nov 20, 2026Latest source record: Feb 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Aug 30, 2018
Primary completion
Jan 3, 2019
Study completion Jan 3, 2019
Sponsor
- Lead sponsor
- Clementia Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Ipsen
- First posted
- Feb 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Dry eye disease (DED) is a keratoconjunctive disorder that "is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. The goal of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple ascending doses of palovarotene ophthalmic solution in healthy adult subjects.
Conditions
- Dry Eye Disease
Interventions
PalovaroteneDrug
ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3
VehicleDrug
Placebo-to-match palovarotene ophthalmic solution vials
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and severity of treatment-emergent ocular adverse events (TEAEs)Time frame: from baseline until the end of study (up to 25 days)
- Change in ocular safety measurements as determined by Best-Corrected Visual Acuity (BCVA)Time frame: from baseline until the end of study (up to 25 days)
- Change in Corneal Fluorescein StainingTime frame: from baseline until the end of study (up to 25 days)
- Change in intraocular pressureTime frame: from baseline until the end of study (up to 25 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Algorithme Pharma facility
Québec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.